Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer’s disease

por Dhadda, Shobha, Kanekiyo, Michio, Li, David, Swanson, Chad J., Irizarry, Michael, Berry, Scott, Kramer, Lynn D., Berry, Donald A.
Publicado 2022

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease

por Honig, Lawrence S., Barakos, Jerome, Dhadda, Shobha, Kanekiyo, Michio, Reyderman, Larisa, Irizarry, Michael, Kramer, Lynn D., Swanson, Chad J., Sabbagh, Marwan
Publicado 2023

Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial

por Berry, Donald A., Dhadda, Shobha, Kanekiyo, Michio, Li, David, Swanson, Chad J., Irizarry, Michael, Kramer, Lynn D., Berry, Scott M.
Publicado 2023

Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 pro...

por McDade, Eric, Cummings, Jeffrey L., Dhadda, Shobha, Swanson, Chad J., Reyderman, Larisa, Kanekiyo, Michio, Koyama, Akihiko, Irizarry, Michael, Kramer, Lynn D., Bateman, Randall J.
Publicado 2022

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

por Swanson, Chad J., Zhang, Yong, Dhadda, Shobha, Wang, Jinping, Kaplow, June, Lai, Robert Y. K., Lannfelt, Lars, Bradley, Heather, Rabe, Martin, Koyama, Akihiko, Reyderman, Larisa, Berry, Donald A., Berry, Scott, Gordon, Robert, Kramer, Lynn D., Cummings, Jeffrey L.
Publicado 2021

Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

por Swanson, Chad J., Zhang, Yong, Dhadda, Shobha, Wang, Jinping, Kaplow, June, Lai, Robert Y. K., Lannfelt, Lars, Bradley, Heather, Rabe, Martin, Koyama, Akihiko, Reyderman, Larisa, Berry, Donald A., Berry, Scott, Gordon, Robert, Kramer, Lynn D., Cummings, Jeffrey L.
Publicado 2022

The AHEAD 3–45 Study: Design of a prevention trial for Alzheimer’s disease

por Rafii, Michael S., Sperling, Reisa A., Donohue, Michael C., Zhou, Jin, Roberts, Claire, Irizarry, Michael C., Dhadda, Shobha, Sethuraman, Gopalan, Kramer, Lynn D, Swanson, Chad J, Li, David, Krause, Stephen, Rissman, Robert A., Walter, Sarah, Raman, Rema, Johnson, Keith A., Aisen, Paul S.
Publicado 2023